Volume 375, 2023, Pages xiii-xixAuthor links open overlay panel, Section snippetsFunding

C.J.-C. is supported by a Margarita Salas fellowship, granted by the University of Seville (Seville, Spain). L.G. is/has been supported (as a PI unless otherwise indicated) by two Breakthrough Level 2 grants from the US DoD BCRP (#BC180476P1; #BC210945), by a grant from the STARR Cancer Consortium (#I16-0064), by a Transformative Breast Cancer Consortium Grant from the US DoD BCRP (#W81XWH2120034, PI: Formenti), by a U54 grant from NIH/NCI (#CA274291, PI: Deasy, Formenti, Weichselbaum), by the

Competing interests

L.G. is/has been holding research contracts with Lytix Biopharma, Promontory, and Onxeo, has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom, and the Luke Heller TECPR2 Foundation, and holds Promontory stock options.

References (74)G. Lazennec et al.Chemokines and chemokine receptors: new insights into cancer-related inflammation

Trends Mol. Med.

(2010)

V. KumarThe nature of myeloid-derived suppressor cells in the tumor microenvironment

Trends Immunol.

(2016)

E. HadadiHeterogeneity and function of macrophages in the breast during homeostasis and cancer

Int. Rev. Cell Mol. Biol.

(2022)

J. DemuytereThe tumor immune microenvironment in peritoneal carcinomatosis

Int. Rev. Cell Mol. Biol.

(2022)

X. CaoTargeting tumor-associated macrophages for cancer immunotherapy

Int. Rev. Cell Mol. Biol.

(2022)

A. BellaOmentum: friend or foe in ovarian cancer immunotherapy?

Int. Rev. Cell Mol. Biol.

(2022)

A. Antonana-VildosolaEnabling CAR-T cells for solid tumors: rage against the suppressive tumor microenvironment

Int. Rev. Cell Mol. Biol.

(2022)

J. AnChronic stress promotes breast carcinoma metastasis by accumulating myeloid-derived suppressor cells through activating beta-adrenergic signaling

Oncoimmunology

(2021)

R. BarnesteinImmunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness

Oncoimmunology

(2022)

R. BitschSTAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice

J. Immunother. Cancer

(2022)

V. BronteRecommendations for myeloid-derived suppressor cell nomenclature and characterization standards

Nat. Commun.

(2016)

A. CalcinottoIL-23 secreted by myeloid cells drives castration-resistant prostate cancer

Nature

(2018)

L. CassettaDifferential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation

J. Immunother. Cancer

(2020)

D. DelittoImplantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection

Oncoimmunology

(2021)

H. DengTranslocation of Helicobacter hepaticus synergizes with myeloid-derived suppressor cells and contributes to breast carcinogenesis

Oncoimmunology

(2022)

D.I. GabrilovichMyeloid-derived suppressor cells

Cancer Immunol. Res.

(2017)

D.I. GabrilovichThe terminology issue for myeloid-derived suppressor cells

Cancer Res.

(2007)

L. GalluzziThe hallmarks of successful anticancer immunotherapy

Sci. Transl. Med.

(2018)

L. GalluzziImmunostimulation with chemotherapy in the era of immune checkpoint inhibitors

Nat. Rev. Clin. Oncol.

(2020)

K.M. HartIL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer

Front. Immunol.

(2011)

M.L. IbrahimMyeloid-derived suppressor cells produce IL-10 to elicit DNMT3b-dependent IRF8 silencing to promote colitis-associated colon tumorigenesis

Cell Rep.

(2018)

M. IlieAssociation of TRF2 expression and myeloid-derived suppressor cells infiltration with clinical outcome of patients with cutaneous melanoma

Oncoimmunology

(2021)

C. Jimenez-CorteganaLow levels of granulocytic myeloid-derived suppressor cells may be a good marker of survival in the follow-up of patients with severe COVID-19

Front. Immunol.

(2021)

C. Jimenez-CorteganaCirculating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial

J. Immunother. Cancer

(2021)

C. Jimenez-CorteganaIncreased blood monocytic myeloid derived suppressor cells but low regulatory T lymphocytes in patients with mild COVID-19

Viral Immunol.

(2021)

C. Jimenez-CorteganaMyeloid-derived suppressor cells and radiotherapy

Cancer Immunol. Res.

(2022)

J. Jin et al.Emerging role of mTOR in tumor immune contexture: impact on chemokine-related immune cells migration

Theranostics

(2020)

View full text

Copyright © 2023 Elsevier Inc. All rights reserved.